Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer

In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab monotherapy in patients with previously treated NSCLC,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodriguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Höglander, Elen, Kaul, Monika, Tolson, Jonathan, Hu, Youyou, Vollan, Hans Kristian, Newsom-Davis, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716834/
https://www.ncbi.nlm.nih.gov/pubmed/36450379
http://dx.doi.org/10.1136/jitc-2022-005581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716834/
https://www.ncbi.nlm.nih.gov/pubmed/36450379
http://dx.doi.org/10.1136/jitc-2022-005581

Ejemplares similares